i

Class I indications for mineralocorticoid receptor anatgonist therapy for reducing the risk of HF hospitalization and reducing the risk of premature death:

- CHF + NYHA Class II - IV symptoms persisting despite treatment with ACEI and B-blocker + LVEF < 35%,
- CHF + NYHA Class II - IV symptoms persisting despite treatment with ARB and B-blocker + LVEF < 35%.


i